Latest news

08/12/2017

Immune cells predict therapy response in breast cancer

When immune cells invade the tumor, this is usually considered a good sign because the body’s own immune system appears to be responding to the cancer. In the case of certain types of breast cancer…

01/12/2017

Versatile cancer drugs

Medications which block enzymes belonging to the kinase family, are among the most effective pharmaceuticals for targeted cancer therapies. Scientists at the German Cancer Consortium (DKTK) at the…

29/11/2017

Lymphoma: Important tumor suppressor discovered in immune cells

Shut-off switch for lymphoma: A safety switch that automatically stops the device for example before it overheats are built into many electrical appliances. The body's cells are also equipped with…

16/11/2017

Dresden scientists develop a sensor for the most important human cancer gene

If it burns in a house smoke detectors alert us hence protecting life. A molecular smoke alert has now been developed by Dresden researchers for the TP53 gene, the most important human cancer gene.…

12/11/2017

Curt Meyer Memorial Prize 2017 awarded to Charité researcher for her 3D model of a tumor’s genetic profile

The Berliner Krebsgesellschaft’s anniversary celebrations included the presentation of the Curt Meyer Memorial Prize 2017. It goes to Soulafa Mamlouk PhD, a biotechnologist at the German Cancer…

08/11/2017

Misregulated protein breakdown promotes leukemias and brain cancer

An enzyme that is responsible for the breakdown of specific amino acids in food plays a key role in the development of leukemias and brain cancer, scientists from the German Cancer Research Center…

10/10/2017

DKTK Program Retreat 2017: Five programs – one aim

At this year’s Program Retreat in Heidelberg from 5 to 6 October, 280 researchers from all the DKTK sites discussed the latest findings and objectives of the consortium’s research programs and…

28/09/2017

Dieter Saur: New DKTK Professor in Munich

Professor Dieter Saur took up the new “Translational Tumor Research” professorship at Klinikum Rechts der Isar, the university hospital of the Technical University of Munich, on 1 August 2017. It is…

21/09/2017

Among the world’s best in radiology

Alexander Radbruch, a radiologist from the German Cancer Consortium (DKTK) German Cancer Research Center (DKFZ) has been recognized by peer professionals to be among the 15 most influential persons…

13/09/2017

Cancer Drug Stimulates Tripolar Mode of Mitosis

Taxanes inhibit cell division and make cancer cells sensitive to radiation therapy. A current study has investigated the underlying mechanisms of this action- and which biomarkers may be useful for…

12/09/2017

Inhibitors support immunotherapy for Leukemia

New immunotherapies are considered a promising lead for treating recurring acute myeloid leukemia (AML). Antibodies are able to eliminate even those cancer cells that cannot be removed via regular…

27/08/2017

Professor Bernd Pichler new member of the Leopoldina

Professor Bernd Pichler, radiologist at the University Hospital of Tübingen, faculty member of DKTK Site in Tübingen and head of the Werner Siemens Imaging Center (WSCI), was elected a member of the…

24/08/2017

Blood test predicts prostate tumor resistance

When bacteria develop antibiotic resistance, treatment with these medications becomes ineffective. Similarly, tumor cells can also change in such a way that renders them resistant to particular…

26/07/2017

Dr Borhane Guezguez: How the tumor creates its niche

Cancer cells are in constant communication with their surroundings. With his new DKTK young investigator group, Dr Borhane Guezguez, an expert on leukemia and stem cell research, is investigating…

17/07/2017

Researcher portrait: School of Oncology Fellow Dr Martin Niklas – Making particle bombardment visible in cancer cells

Tumors that surgeons cannot reach can be destroyed accurately using particle therapy. Dr Martin Niklas has developed a biosensor with living cancer cells to make visible the effect of particle…

30/06/2017

Targeted countermeasure for altering tumors

In most cases, renal cancer is well responsive to targeted medication; even if there have been occurrences of therapy resistance. However, the choice of the adequate medication is crucial in order to…

23/06/2017

Professor Marc Timmers elected to the EMBO

On 16 June, Professor Marc Timmers, the new Professor of Medical Epigenetics within the German Cancer Consortium (DKTK), was elected to join the European Molecular Biology Association (EMBO). The EMBO…

13/06/2017

Mysterious gene transcripts after cancer therapy

Drugs that are used in cancer therapy to erase epigenetic alterations in cancer cells simultaneously promote the production of countless mysterious gene transcripts, scientists from the German Cancer…

31/05/2017

DKTK Essen/Düsseldorf: New findings support immunotherapy of skin cancer

Merkel cell carcinoma of the skin is often invisible for the body’s immune defense because it silences specific genes of the immune system. Scientists from the German Cancer Consortium (DKTK) at the…

22/05/2017

New faculty member: Prof. Matthias Eder

Professor Matthias Eder took up his post as DKTK Professor of Radiopharmaceuticals Development at the University of Freiburg’s Faculty of Medicine on 1 May 2017.